Login to Your Account



AlgoRx's Series C Round Gets $65M For Phase II Compounds

By Kim Coghill


Wednesday, February 25, 2004
AlgoRx Pharmaceuticals Inc. intends to use proceeds from its $65 million Series C financing to bankroll ongoing development of its two lead Phase II drug candidates. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription